ClinicalTrials.gg
RecruitingNCT06906640IRIS-CKDUpdated Oct 1, 2026

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

An interventional study of (IRIS-CKD Management Program): Education and (IRIS-CKD Management Program): GDMT in Chronic Kidney Disease(CKD), Type 2 DM and Type 2 Diabetes Mellitus (T2DM), sponsored by Duke University. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 1, 2026Enrollment updatedSponsor changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Renal Insufficiency, Chronic by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Renal Insufficiency, Chronic · Duke University.

Planned enrollment
7th of 18
212 · median 136
Started
2025
with 3 others
No phase
15 of 20
4 open now
Registered
17th of 20
by date

Among the 20 studies in Renal Insufficiency, Chronic by Duke University, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 15 with no phase, and was the 17th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 20 studies in Renal Insufficiency, Chronic by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Renal Insufficiency, Chronic by Duke University, or all of them as a file.
02

Study summary

IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

Read the detailed description

IRIS-CKD Management Program: will compare prescriptions for guideline-directed medical therapies (GDMT) during the study period. To account for variable GDMT requirements, we will use opportunity scores to compare intervention arms. Patients will be screened, identified and undergo consent by the study site. Patients will receive educational materials related to CKD screening in T2D and details regarding the testing intervention study as per site specific recruitment requirements. The primary objective is to determine whether implementing a guided management program versus education alone will improve prescription of GDMT for people with CKD and T2D. Patients will complete approximately 6 months of follow-up.

03

Conditions studied

  • Chronic Kidney Disease(CKD)
  • Type 2 DM
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • CKD
  • T2DM
  • T2D
  • Type 2 Diabetes
  • Chronic kidney disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (CKD Management)

    • Adults with type 2 diabetes (T2D)
    • Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
    • Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):

      • UACR >300 mg/g or
      • \<45 ml/min/1.73 m2 or
      • UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2
    • Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).

Exclusion criteria

Exclusion Criteria:

  • (CKD Management)

    • Type 1 diabetes
    • Most recent \<20 ml/min/1.73 m2
    • Prior kidney transplant
    • Autosomal dominant polycystic kidney disease (ADPKD)
    • Active pregnancy or plans for conception within 1 year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Active comparator
    (IRIS-CKD Management Program): Education

    Education: Participants will receive targeted educational materials related to their stage of CKD, including recommendations for potential GDMT to discuss with their primary care provider.

    Other: (IRIS-CKD Management Program): Education

  • Active comparator
    (IRIS-CKD Management Program): GDMT

    Management: Participants will receive targeted educational materials, along with GDMT prescription, dose titration, and laboratory monitoring by a pharmacist/APP, as necessary, with guidance from a centralized algorithm and oversight from a nephrologist site PI.

    Other: (IRIS-CKD Management Program): Education · Other: (IRIS-CKD Management Program): GDMT

Interventions

  • Other(IRIS-CKD Management Program): Education

    Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.

  • Other(IRIS-CKD Management Program): GDMT

    Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.

06

What researchers measure

Primary outcomes

  1. CKD GDMT Opportunity Score at 6 months

    Opportunity score of GDMT prescriptions at 6 months that were missing at baseline. The score will include prescriptions for GDMT that are active at month 6 or the loss of an indication for the GDMT.

    Time frame: 6 months

Secondary outcomes

  1. CKD GDMT Opportunity Score at 6 months weighted by dose

    Change in opportunity score from baseline to 6 months weighted by prescribed dose of GDMT.

    Time frame: 6 months

  2. CKD GDMT Opportunity Score at 3 months

    Opportunity score of GDMT prescriptions at 3 months that were missing at baseline. The score will include prescriptions for GDMT that are active at month 3 or the loss of an indication for the GDMT.

    Time frame: 3 months

Other outcomes

  1. UACR change

    Change in UACR after 6 months

    Time frame: 6 months

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 17 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Apr 2, 2025
StartActual
Oct 28, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
420→212
Oct 1, 2026
Contact
Study contact changed: m•••@duke.edu→l•••@duke.edu. See the current contact
Oct 1, 2026
Sponsor
Collaborators removed: Eli Lilly and Company
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Enrollment 420→212
    Sponsor Collaborators removed: Eli Lilly and Company
    Contact Study contact changed: m•••@duke.edu→l•••@duke.edu. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06906640
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Oct 28, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Gretchen Sanders, MSN
Contact
gretchen.sanders@duke.edu
919 6687829
lisa monk, MSN
Contact
lisa.monk@duke.edu
Neha Pagidipati, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion